Trials / Completed
CompletedNCT04937387
Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma
A Phase III, 12 Week, Randomized, Double-blind, 4 Arm Parallel Group Bridging Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI Once-daily Via a Dry Powder Inhaler With Dual Combination of FF/VI, Administered in Chinese Participants With Inadequately Controlled Asthma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 359 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study aims to evaluate the efficacy, safety and tolerability of FF/UMEC/VI compared with FF/VI via ELLIPTA® inhaler in Chinese participants with inadequately controlled asthma. ELLIPTA is a registered trademark of GlaxoSmithKline group of companies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FF/VI | FF/VI will be administered. |
| DRUG | FF/UMEC/VI | FF/UMEC/VI will be administered. |
| DEVICE | ELLIPTA | FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler. |
Timeline
- Start date
- 2021-07-29
- Primary completion
- 2024-08-05
- Completion
- 2024-08-05
- First posted
- 2021-06-24
- Last updated
- 2025-08-11
- Results posted
- 2025-08-11
Locations
61 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04937387. Inclusion in this directory is not an endorsement.